Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · IEX Real-Time Price · USD
8.20
0.00 (0.00%)
At close: Apr 24, 2024, 4:00 PM
8.48
+0.28 (3.41%)
After-hours: Apr 24, 2024, 7:49 PM EDT
Company Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | May 13, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | C. Russell Trenary III |
Contact Details
Address: 485 Route 1 South, Building F, Suite 320 Iselin, New Jersey 08830 United States | |
| Phone | (609) 619-3990 |
| Website | outlooktherapeutics.com |
Stock Details
| Ticker Symbol | OTLK |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001649989 |
| CUSIP Number | 69012T206 |
| ISIN Number | US69012T3059 |
| Employer ID | 38-3982704 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ralph H. Thurman | Independent Executive Chairman |
| C. Russell Trenary III | President, Chief Executive Officer and Director |
| Lawrence A. Kenyon CPA | Executive Vice President, Chief Financial Officer, Treasurer, Company Secretary and Director |
| Jeffrey Evanson | Chief Commercial Officer |
| Alicia Tozier | Senior Vice President, Marketing and Market Access |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development and Regulatory Affairs |
| Jedd Comiskey | Senior Vice President - Head of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 16, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 424B5 | Filing |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | EFFECT | Notice of Effectiveness |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | 424B3 | Prospectus |